NZ720273A - Preparations and methods for treating a gd2 positive cancer - Google Patents

Preparations and methods for treating a gd2 positive cancer

Info

Publication number
NZ720273A
NZ720273A NZ720273A NZ72027314A NZ720273A NZ 720273 A NZ720273 A NZ 720273A NZ 720273 A NZ720273 A NZ 720273A NZ 72027314 A NZ72027314 A NZ 72027314A NZ 720273 A NZ720273 A NZ 720273A
Authority
NZ
New Zealand
Prior art keywords
patient
positive cancer
preparations
methods
treating
Prior art date
Application number
NZ720273A
Other languages
English (en)
Inventor
Hans Loibner
Oliver Mutschlechner
Ruth Ladenstein
Isabel Klier
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13193953.0A external-priority patent/EP2875827A1/en
Priority claimed from CA2834000A external-priority patent/CA2834000A1/en
Priority claimed from US14/182,776 external-priority patent/US10294305B2/en
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of NZ720273A publication Critical patent/NZ720273A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ720273A 2013-11-21 2014-11-21 Preparations and methods for treating a gd2 positive cancer NZ720273A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201314086696A 2013-11-21 2013-11-21
EP13193953.0A EP2875827A1 (en) 2013-11-21 2013-11-21 Preparations and methods for treating a GD2 positive cancer
CA2834000A CA2834000A1 (en) 2013-11-21 2013-11-21 Method for treating a gd2 positive cancer
US14/182,776 US10294305B2 (en) 2012-06-18 2014-02-18 Method for treating a GD2 positive cancer
PCT/EP2014/075315 WO2015075194A1 (en) 2013-11-21 2014-11-21 Preparations and methods for treating a gd2 positive cancer

Publications (1)

Publication Number Publication Date
NZ720273A true NZ720273A (en) 2022-02-25

Family

ID=53179006

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ720273A NZ720273A (en) 2013-11-21 2014-11-21 Preparations and methods for treating a gd2 positive cancer

Country Status (19)

Country Link
US (3) US10995147B2 (https=)
EP (2) EP3620173A1 (https=)
JP (2) JP6693873B2 (https=)
AU (2) AU2014351796B2 (https=)
CA (1) CA2930285A1 (https=)
CY (1) CY1122508T1 (https=)
DK (1) DK3071220T3 (https=)
EA (1) EA201691055A1 (https=)
ES (1) ES2768649T3 (https=)
HR (1) HRP20200128T1 (https=)
HU (1) HUE047920T2 (https=)
LT (1) LT3071220T (https=)
NZ (1) NZ720273A (https=)
PL (1) PL3071220T3 (https=)
PT (1) PT3071220T (https=)
RS (1) RS59817B1 (https=)
SI (1) SI3071220T1 (https=)
SM (1) SMT202000027T1 (https=)
WO (1) WO2015075194A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
DK3071220T3 (da) * 2013-11-21 2020-02-10 Apeiron Biologics Ag Præparater til at behandle en gd2-positiv cancer
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
EP3684818A2 (en) * 2017-09-21 2020-07-29 UMC Utrecht Holding B.V. Anti-gd2 antibody for the treatment of neuroblastoma
US20230295339A1 (en) * 2020-07-06 2023-09-21 Eusa Pharma (Uk) Limited Method for treating a gd2-positive cancer
WO2026053122A1 (en) * 2024-09-04 2026-03-12 Dana-Farber Cancer Institute, Inc. Methods of treating retinoid responsive cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
EP1916257A1 (en) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
US8278065B2 (en) 2008-06-30 2012-10-02 Morphotek, Inc. Polynucleotides encoding anti-GD2 antibodies
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
JP5623999B2 (ja) 2010-08-31 2014-11-12 パナソニック株式会社 電子装置
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9777068B2 (en) 2012-06-18 2017-10-03 Apeiron Biologics Ag Method for treating a GD2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
DK3071220T3 (da) * 2013-11-21 2020-02-10 Apeiron Biologics Ag Præparater til at behandle en gd2-positiv cancer

Also Published As

Publication number Publication date
JP7139293B2 (ja) 2022-09-20
JP2019218359A (ja) 2019-12-26
DK3071220T3 (da) 2020-02-10
US11492412B2 (en) 2022-11-08
AU2014351796A2 (en) 2016-08-11
PL3071220T3 (pl) 2020-05-18
LT3071220T (lt) 2020-02-25
HRP20200128T1 (hr) 2020-05-15
JP2016539122A (ja) 2016-12-15
AU2014351796B2 (en) 2020-02-27
ES2768649T3 (es) 2020-06-23
JP6693873B2 (ja) 2020-05-13
WO2015075194A1 (en) 2015-05-28
RS59817B1 (sr) 2020-02-28
SI3071220T1 (sl) 2020-03-31
US20210221909A1 (en) 2021-07-22
CA2930285A1 (en) 2015-05-28
US10995147B2 (en) 2021-05-04
AU2020203346A1 (en) 2020-06-11
EP3071220A1 (en) 2016-09-28
PT3071220T (pt) 2020-02-03
US20240158530A1 (en) 2024-05-16
SMT202000027T1 (it) 2020-03-13
EP3071220B1 (en) 2019-12-25
HK1223039A1 (en) 2017-07-21
US20200332021A1 (en) 2020-10-22
CY1122508T1 (el) 2021-05-05
EA201691055A1 (ru) 2016-11-30
EP3620173A1 (en) 2020-03-11
AU2014351796A1 (en) 2016-05-26
HUE047920T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
NZ720273A (en) Preparations and methods for treating a gd2 positive cancer
MX373301B (es) Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
MY188139A (en) Sodium channel modulators for the treatment of pain
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
PH12016502354A1 (en) Pharmaceutical composition
MX2017015896A (es) Agente anticancerigeno.
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
MX2015014773A (es) Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
MX2017000366A (es) Terapia de combinacion para el cancer.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2015013091A (es) Metodos mejorados de uso para secretoglobinas humanas recombinantes.
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
MX2019003751A (es) Proteina terapeutica.
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2023 BY CPA GLOBAL

Effective date: 20221007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2024 BY CPA GLOBAL

Effective date: 20231006

LECA Licensee/mortgages/financial interest

Name of requester: EUSA PHARMA

Effective date: 20231123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251010